Invest in Immunome Inc on Stash
Immunome Inc. is a biopharmaceutical company utilizing its human memory B cell platform to discover and develop antibody therapeutics. The Company’s primary focus is oncology. Its discovery platform identifies novel therapeutic antibodies and their targets by leveraging highly educated components of the immune system, memory B cells, from patients who have learned to fight off their disease. Its lead discovery programs include IMM-ONC-01 and IMM-BCP-01. Its lead oncology program is focused on IL-38. It is engaged in the research and development of the antibody mixture. IMM-BCP-01 is its lead infectious disease discovery program with a focus on SARS-CoV-2.
Ticker: IMNM
Immunome Inc
$19.75
+5.90%
$
IMNM Performance Breakdown
Share Price
$19.75
Today's change
1.96%
Year to date change (YTD)
87.56%
Dividend yield
0.0
Last dividend paid
N/A
Last dividend pay date
N/A
About IMNM
Immunome Inc. is a biopharmaceutical company utilizing its human memory B cell platform to discover and develop antibody therapeutics. The Company’s primary focus is oncology. Its discovery platform identifies novel therapeutic antibodies and their targets by leveraging highly educated components of the immune system, memory B cells, from patients who have learned to fight off their disease. Its lead discovery programs include IMM-ONC-01 and IMM-BCP-01. Its lead oncology program is focused on IL-38. It is engaged in the research and development of the antibody mixture. IMM-BCP-01 is its lead infectious disease discovery program with a focus on SARS-CoV-2.
Immunome Inc Stock Ticker
IMNM
For more information
Invest in Immunome Inc on Stash
Immunome Inc. is a biopharmaceutical company utilizing its human memory B cell platform to discover and develop antibody therapeutics. The Company’s primary focus is oncology. Its discovery platform identifies novel therapeutic antibodies and their targets by leveraging highly educated components of the immune system, memory B cells, from patients who have learned to fight off their disease. Its lead discovery programs include IMM-ONC-01 and IMM-BCP-01. Its lead oncology program is focused on IL-38. It is engaged in the research and development of the antibody mixture. IMM-BCP-01 is its lead infectious disease discovery program with a focus on SARS-CoV-2.
Certain companies are volatile
Certain companies can be volatile, meaning the stock price fluctuates significantly. Don’t put all your eggs into one basket and remember to keep the Stash Way in mind when you invest.
Immunome Inc stock news
Why invest with Stash?
Fractional shares
Thousands of stocks and ETFs. No investing minimums.
Unlimited trades
Plus no add-on trading commission fees.†
Diversification analysis
Custom investment recommendations can help you diversify.
Automatic investing
Dividend reinvestment,8 recurring investments, and more.
The Stock-Back® Card
We’ll give you matching stock in companies you shop at.1
Learn how to invest
Get professional advice and education at every step.
How to buy Immunome Inc stock on Stash
Stash allows you to purchase smaller, more affordable pieces of investments (called fractional shares) rather than the whole share, which can be significantly more expensive.
Stash offers two subscription plans: Stash Growth and Stash+.
Once your market order of Immunome Inc stock is complete, you'll officially be a shareholder of Immunome Inc!
Invest in Immunome Inc on Stash
Immunome Inc. is a biopharmaceutical company utilizing its human memory B cell platform to discover and develop antibody therapeutics. The Company’s primary focus is oncology. Its discovery platform identifies novel therapeutic antibodies and their targets by leveraging highly educated components of the immune system, memory B cells, from patients who have learned to fight off their disease. Its lead discovery programs include IMM-ONC-01 and IMM-BCP-01. Its lead oncology program is focused on IL-38. It is engaged in the research and development of the antibody mixture. IMM-BCP-01 is its lead infectious disease discovery program with a focus on SARS-CoV-2.



